摘要
目的 探讨司美格鲁肽治疗糖尿病肾病的效果。方法 选择2020年7月—2021年10月在吉林市化工医院治疗的糖尿病肾病患者94例为研究对象,以随机数表法分为对照组和观察组,每组47例。对照组皮下注射艾塞那肽治疗,观察组皮下注射司美格鲁肽治疗。治疗后,比较两组患者血糖、肾功能和血压指标。结果治疗后,观察组空腹血糖和餐后2 h血糖水平分别为(6.79±1.45)、(8.88±1.49)mmol/L,低于对照组的(7.61±1.67)、(9.63±1.80)mmol/L;观察组24 h尿蛋白和血清肌酐水平分别为(1.56±0.31)g/d、(80.19±6.64)μmol/L,低于对照组的(1.78±0.37)g/d、(85.26±6.56)μmol/L;观察组舒张压和收缩压水平分别为(81.50±7.71)、(130.66±7.51)mmHg,低于对照组的(85.26±7.92)、(134.46±9.12)mmHg,差异有统计学意义(P<0.05)。结论 司美格鲁肽有效改善了糖尿病肾病患者的血糖、肾功能和血压等指标,治疗效果较为理想。
Objective To investigate the effect of semaglutide in the treatment of diabetic nephropathy.Methods A total of 94 patients with diabetic nephropathy who were treated in Jilin Chemical Hospital from July 2020 to October 2021 were selected as the research subjects.By random number table method,they were divided into control group and observation group,with 47 patients in each group.The control group received subcutaneous injection of exenatide.The observation group was treated with subcutaneous injection of semaglutide.After treatment,blood glucose,renal function and blood pressure indexes were compared between the two groups.Results After treatment,the fasting blood glucose and 2 h postprandial blood glucose levels of the observation group were(6.79±1.45) mmol/L,(8.88±1.49)mmol/L,respectively,lower than those of the control group(7.61±1.67) mmol/L,(9.63±1.80) mmol/L;the 24-hour urine protein and serum creatinine levels in the observation group were(1.56±0.31) g/d,(80.19±6.64) μmol/L,respectively,lower than those in the control group(1.78±0.37) g/d,(85.26±6.56) μmol/L;the levels of diastolic blood pressure and systolic blood pressure in the observation group were(81.50±7.71) mmHg and(130.66±7.51) mmHg,respectively,which were lower than those in the control group(85.26±7.92) mmHg and(134.46±9.12) mmHg,and the difference was statistically significant(P<0.05).Conclusion Semaglutide can effectively improve the indicators of blood glucose,renal function and blood pressure in patients with diabetic nephropathy,and the therapeutic effect is ideal.
作者
袁丽
YUAN Li(Department of Endocrinology,Jilin Chemical Hospital,Jilin,Jilin Province,132021 China)
出处
《糖尿病新世界》
2022年第18期191-194,共4页
Diabetes New World Magazine
关键词
司美格鲁肽
糖尿病肾病
血糖
肾功能
血压
Semaglutide
Diabetic nephropathy
Blood glucose
Renal function
Blood pressure
